Informations générales (source: ClinicalTrials.gov)

NCT05803941 En recrutement IDF
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer
Interventional
  • Tumeurs de la prostate
Phase 4
Novartis Pharmaceuticals (Voir sur ClinicalTrials)
août 2023
juillet 2033
25 avril 2025
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY Camilo GARCIA En recrutement IDF 27/04/2026 08:20:06  Contacter
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Novartis Investigative Site - 69373 - Lyon - France En recrutement Contact (sur clinicalTrials)

Critères

Homme
Inclusion Criteria:

- Signed informed consent must be obtained prior to participation in the study

- Must have received at least one dose of AAA617 within an interventional, Phase I-IV
Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's
requirements that allows them to participate in this study.


- Inability to complete the needed investigational examinations due to any reason.